1-(2-pyrimidyl)pyrrolidine-2,5-dione | 37454-74-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-(2-pyrimidyl)pyrrolidine-2,5-dione
• 英文别名: 1-Pyrimidin-2-ylpyrrolidine-2,5-dione；1-pyrimidin-2-ylpyrrolidine-2,5-dione
• CAS: 37454-74-3
• 化学式: C₈H₇N₃O₂
• 分子量: 177.162
• InChiKey: YEEVOZHRRAHGLD-UHFFFAOYSA-N

物化性质

• 沸点：
  365.9±25.0 °C(Predicted)
• 密度：
  1.435±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  63.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2-pyrimidyl)pyrrolidine-2,5-dione 、 三氯化铬 以 乙醇 为溶剂， 以72%的产率得到(bis(2-(N-succinimidyl)pyrimidine)dichromium(III) chloride)
  参考文献：
  名称：

  Zaidi, S. A. A.; Shahjahan; Sharif, M., Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry, 1993, vol. 23, p. 1571 - 1584

  摘要：

  DOI：
• 作为产物：
  描述：

  1,3,5-三嗪-2,4,6-三胺,N,N'''-1,2-乙二基二[N-[3-[[4,6-二[丁基(2,2,6,6-四甲基-4-哌啶基)氨基]-1,3,5-三嗪-2-基]氨基]丙基]-N,N''-二丁基-N,N''-二(2,2,6,6-四甲基-4-哌啶基)- 、 丁二酸酐 在 乙酸酐 作用下， 以 丙酮 、 甲苯 为溶剂， 反应 75.0h， 以32%的产率得到1-(2-pyrimidyl)pyrrolidine-2,5-dione
  参考文献：
  名称：

  NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS

  摘要：

  神经保护多功能抗氧化剂是含有2-二乙酰氨基-5-羟基嘧啶基团的化合物，具有以下结构式： 其中R1为CH2或C2H4；R2为H或—OR4，其中R4为H或芳基；R3a和R3b分别独立地选自H和—O-烷基的组。这些抗氧化剂是口服可利用的金属减弱多功能抗氧化剂，可以独立减弱过渡金属，以及清除自由基。由于这些多功能抗氧化剂化合物具有独立螯合金属（如Fe、Cu或Zn）和清除来自不同来源产生的自由基的能力，它们具有神经保护作用，并有助于治疗各种神经系统疾病，如阿尔茨海默病、帕金森病、肌萎缩侧索硬化症、创伤性脑损伤、眼部疾病（如白内障、青光眼、老年性黄斑变性和其他视网膜变性），以及减缓糖尿病并发症的进展。

  公开号：

  US20140235858A1

文献信息

• Orally Bioavailable Metal Chelators and Radical Scavengers: Multifunctional Antioxidants for the Coadjutant Treatment of Neurodegenerative Diseases
  作者：Hiroyoshi Kawada、Peter F. Kador

  DOI：10.1021/acs.jmedchem.5b00272

  日期：2015.11.25

  Neurodegenerative diseases are associated with oxidative stress that is induced by the presence of reactive oxygen species and the abnormal cellular accumulation of transition metals. Here, a new series of orally bioavailable multifunctional antioxidants (MFAO-2s) possessing a 2-diacetylamino-5-hydroxypyrimidine moiety is described. These MFAO-2s demonstrate both free radical and metal attenuating properties that are similar to the original published MFAO-1s that are based on 1-N,N'-dimethylsulfamoyl-1-4-(2-pyrimidyl)piperazine. Oral bioavailability studies in C57BL/6 mice demonstrate that the MFAO-2s accumulate in the brain at significantly higher levels than the MFAO-1s while achieving similar neural retina levels. The MFAO-2s protect human neuroblastoma and retinal pigmented epithelial cells against hydroxyl radicals in a dose-dependent manner by maintaining cell viability and intracellular glutathione levels. The MFAO-2s outperform clioquinol, a metal attenuator that has been investigated for the treatment of Alzheimer's disease.
• EP2956140A1
  申请人：——

  公开号：EP2956140A1

  公开（公告）日：2015-12-23
• US7919082B1
  申请人：——

  公开号：US7919082B1

  公开（公告）日：2011-04-05
• US8877766B2
  申请人：——

  公开号：US8877766B2

  公开（公告）日：2014-11-04
• [EN] NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS<br/>[FR] ANTIOXYDANTS MULTIFONCTIONNELS NEUROPROTECTEURS ET LEURS ANALOGUES MONOFONCTIONNELS
  申请人：KADOR PETER F

  公开号：WO2014126596A1

  公开（公告）日：2014-08-21

  The neuroprotective multifunctional antioxidants are compounds that contain a 2-diacetylamino-5-hydroxypyrimidine moiety, having the structural formula: wherein R1 is CH2 or C2H4; R2 is H or -OR4 where R4 is H or aryl; and R3a and R3b are independently selected from the group consisting of H and -O-alkyl. The antioxidants are orally bioavailable metal-attenuating multifunctional antioxidants that can independently attenuate transition metals, as well as scavenger free radicals. The multifunctional antioxidant compounds, by their ability to independently chelate metals, such as Fe, Cu or Zn, and scavenge free radicals generated from different sources, are neuroprotective and are beneficial for the treatment of various neurological disorders, such as Alzheimer's disease, Parkinson's disease, ALS, traumatic brain injury, ocular disorders, such as cataract, glaucoma, age-related macular degeneration and other retinal degeneration, as well as for reducing the progression of diabetic complications.